Biogen Inc. ? will present new data and updates from its spinal muscle atrophy (SMA) research programs, including high dose nusinersen and salanersen, at the 2026 Muscular Dystrophy Association (MDA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results